Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Cancers (Basel) · 2025 · PMC12070846 · PMID 40361370

Europe PMC DOI

hedged sentences

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

borderline significancep -value = 0.059so close (0.05 < p ≤ 0.1)

Regarding the above mentioned differences between the two radiation dose groups ( Table 2 ), MVA revealed that the only significant factor that impacts LC is histology (N = 188; HR 2.234 95%-CI 1.399–3.566; p -value < 0.001; Table 3 ) with total radiation dose (>/<66 Gy) showing borderline significance ( p -value = 0.059).

also in 7,017 other papers

highly significantno p-value reported

However, the results presented by this group reveal a highly significant benefit of Durvalumab treatment with respect to local control (LC).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation &gt; 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

The sentences

Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).